Elizabeth Eden

• An unwavering twenty-two commitment to provide kind, safe, comprehensive, evidence-based, patient-centered care to pediatric patients and their caregivers.
• Dedication in multiple settings, including Radiation Oncology, Neuro-Oncology, and Multidisciplinary Oncology Clinics.
• A lifelong learner seeking knowledge as a power to improve patient outcomes. Most recently, became double board certified as a Pediatric Mental Health Specialist.

• National Award: Association of Pediatric Nurse Practitioner - Pediatric Nurse Practitioner of the Year, Arizona. 2024
• Alumni Award: Gustavus Excellence in Nursing Award 2024
• Costco Grant ($50K) awarded for Mayo Radiation Oncology, Costco Book Nook and Go Gold Shoe Initiative, 2024
• National Award: Advanced Practice Community Impact Award, Pediatric Nursing Certification Board, Mayo Clinic, 2023
• 2022 Top Performer for Top Performance in Likelihood to Recommend, The Office of Mayo Clinic Experience, Mayo Clinic.
• Beam Award Recipient, Department of Radiology, Mayo Clinic, 2023
• Excellence Recognition Award, Mayo Clinic Arizona, 2022
• Graduated Summa Cum Laude, Masters in Pediatric Nursing, 2009
• Alumni Chapter Book Scholarship, Alumni Association, Arizona State University, 2009
• First Decade Award Nominee, Gustavus Adolphus College, 2009
• Outstanding Graduate Student Award, Arizona State University, 2009
• Graduate Fellowship Award, Arizona State University, 2008
• Nominee - Recognizing Outstanding Women Graduate Students, Prescott Chapter, Philanthropic Educational Organization, 2008
• Scholarship Recipient, Homa and Irene Wood Foundation, Arizona State University, 2008
• Graduate Student Merit Scholarship, Graduate Nurses Organization, Arizona State University, 2007
• Role Model Status, Phoenix Children's Hospital, 2007
• Leader in Education and Training - Recognized by Peers, Phoenix Children's Hospital, 2006
• Dean's List, Gustavus Adolphus College, 2003
• Graduation with Honors, Gustavus Adolphus College, 2003

• American Society of Pediatric Hematology/Oncology, National Member, 2024 - Present
• International Society of Paediatric Oncology, International Member, 2024 - Present
• National Association of Pediatric Nurse Practitioners, Member, 2008 - Present
• Sigma Theta Tau International, Inducted Member, 2003 - 2014

• Cross Middle School, Eighth Grade Boy's Basketball Volunteer Coach, 2025
• Pediatric Cancer Alliance (AZ Non-profit), Founder, President and Board Director, 2024-Present
• Go Gold Shoe Initiative, Volunteer, 2024-Present
• Children's Cancer Network, Volunteer Race Photographer, 2023-2024
• Holiday Foster Family Adoptions, Volunteer, 2022-2023
• Champ Run/Walk Pediatric Cancer Event, Team Co-Captain, 2022
• Run to Fight Children's Cancer, Team Captain, 2022-2023
• Ben Franklin Charter School, Basketball League Coach, 2022
• Casteel High School, Volunteer Photographer 2022-2024
• Benjamin Franklin Charter School Football League, Volunteer Coach, 2022
• Benjamin Franklin Charter School, Volunteer Photographer, 2022
• STEM Program, Volunteer, Fundraiser, 2022 - 2023
• Healthy Kids Running Series, Volunteer Race Photographer, 2014 - 2015
• Queen Creek Volunteer Youth Flag Football Program, Volunteer, 2023
• Rockpoint Church, Volunteer Photographer, 2018 - 2019

2017-2020

• BRF116013 - Novartis - Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advance BRAF V600-Mutation Positive Solid Tumors.
• MEK116540 - Novartis - An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutation
• CDRB436G2201 - Novartis - Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)
• AflacST1501 - CHOA - Phase I Study of Abemaciclib (LY2835219) inhibitor of Cyclin-dependent kinases 4 and 6 (Cdk4/6) in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Recurrent or Refractory Malignant Brain and Solid Tumors
• AflacST1502 - CHOA - A Phase II Study in Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
• Quality Improvement Project: Prevention and stepwise treatment of skin side effects with targeted molecular therapies (MEK and B-RAF).
• Retrospective Chart Review of Pediatric Patients with Atypical Teratoid Rhabdoid Tumors Phoenix Children's Hospital from 2000-2017.

2015- 2016 

• A Phase 3, 12 Week, Double-Blind, Randomized, Parallel-Group, Multicenter study Investigating the Efficiency and Safety of Symbicort pMDI 80/25ug, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5ug 2 Actuations Twice Daily, Compared with Budesonide pMDI 80ug 2 Actuations Twice Daily, in Children Ages 6 to<12 Years with Asthma (CHASE III)
• 2015-2015 A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort , a fixed combination of inhaled corticosteroid (ICS) (Budesonide) and a long acting ß2-agonist (LABA) (Formoterol) as compared to treatment with ICS (Budesonide) alone in adult and adolescent (=12 years of age) patients with asthma (LABA)
• 2013- Sub Investigator. Investigation # AER-047. "A randomized, single-visit, clinical validation study to assess the degree of agreement of FeNO measured with the NIOX VERO device using the 6 second exhalation mode and 10 second exhalation mode in subjects 6-10 years of age with asthma and to assess the ability of subjects 4-5 years of age with asthma to use the NIOX VERO device for measuring FeNO with the 6 second exhalation mode and 10 second exhalation mode"